Encorafenib: Interim Phase Ib/II data

Interim data from 102 patients with advanced BRAF mutation-positive mCRC who failed >=1 prior therapy in an open-label, international Phase Ib/II trial showed that once-daily 200 mg oral

Read the full 286 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE